CXCR2 and atherosclerosis: Some CXCR2- and CCR2-specific antagonists (i.e., reparixin and MLN1202) have already been tested as therapeutic drugs in clinical trials, like MLN1202, which is a CCR2-blocking monoclonal antibody shown to reduce high-sensitivity CRP as surrogate parameter for atherosclerosis (Allegretti et al., 2008; Gilbert et al., 2011).